RMC No. 127-2021 clarifies that Liraglutide is VAT-exempt only for diabetes management, while Saxenda for obesity or weight management is not covered.
Businesses dealing with Liraglutide 6mg/mL Solution for Injection (SC) must not treat every sale or purchase of the product as automatically VAT-exempt. Under RMC No. 127-2021, the tax treatment turns on the product’s actual use: it is considered VAT-exempt only when used for the management of diabetes. When the same Liraglutide formulation is sold under the brand name Saxenda for the management of overweight and obesity, it does not fall within the diseases identified under the TRAIN Law and the CREATE Act for VAT-exempt treatment.
What Changed Under RMC No. 127-2021
RMC No. 127-2021 publishes the clarification from the Food and Drug Administration on a query involving the list of VAT-exempt products. The central point is specific and commercially important: Liraglutide 6mg/mL Solution for Injection (SC) is not VAT-exempt in all cases merely because it is a medicine or because it contains the same active formulation. Its VAT exemption depends on whether the use falls under the management of diabetes.
The clarification is particularly important because the same active pharmaceutical product may be associated with different therapeutic uses, branding, marketing, and regulatory positioning. The circular identifies Liraglutide 6mg/mL Solution for Injection (SC) as being VAT-exempt only if its use falls under diabetes management. It further clarifies that Liraglutide 6mg/mL Solution for Injection (SC) under the brand name Saxenda, when used for management of overweight and obesity, is not within the diseases identified in the TRAIN Law and the CREATE Act.
For Philippine VAT compliance, this means businesses should not rely solely on the generic name, dosage, formulation, or injectable form of the product. The controlling compliance question is whether the product, as sold and used, qualifies under the identified VAT-exempt diseases. For this particular issuance, diabetes management is the qualifying use stated in the clarification, while management of overweight and obesity is expressly excluded.
Who Is Affected
RMC No. 127-2021 affects pharmaceutical companies, importers, distributors, wholesalers, drugstores, hospitals, clinics, prescribing networks, accounting teams, VAT-registered sellers, and corporate buyers dealing with Liraglutide 6mg/mL Solution for Injection (SC). It is also relevant to CFOs and tax managers reviewing VAT invoices, official receipts, purchase orders, product listings, enterprise resource planning classifications, and tax codes used for medicines.
The issuance is especially relevant to businesses that carry both diabetes-related products and weight-management products. A company may be exposed to VAT classification errors if it applies one VAT treatment across all Liraglutide products without checking the brand, indicated use, and supporting documentation. For example, a product sold for diabetes management may be treated differently from Liraglutide under the brand name Saxenda when the relevant use is management of overweight and obesity.
Pharmacies and distributors should also pay attention to product master files and point-of-sale tax settings. If a system automatically tags Liraglutide 6mg/mL Solution for Injection (SC) as VAT-exempt without distinguishing use or brand context, the business may undercharge VAT on products that do not qualify for VAT exemption under the clarification.
Key Compliance Requirement: Determine the Use Before Applying VAT Exemption
The key compliance requirement is to validate the basis for VAT exemption before classifying the product as VAT-exempt. RMC No. 127-2021 does not create a blanket exemption for Liraglutide 6mg/mL Solution for Injection (SC). It recognizes VAT-exempt treatment only when the product’s use falls under the management of diabetes.
For accounting and tax teams, the practical rule is straightforward: review whether the sale involves Liraglutide 6mg/mL Solution for Injection (SC) for diabetes management. If the sale involves Liraglutide 6mg/mL Solution for Injection (SC) under the brand name Saxenda for management of overweight and obesity, the issuance states that it does not fall under the identified diseases included in both the TRAIN Law and the CREATE Act. The product should therefore not be treated as VAT-exempt on that basis.
The date of the circular is December 16, 2021. The FDA letter referred to in the circular is dated November 15, 2021. Businesses reviewing transactions, product tax codes, or historical VAT treatment should use these dates when checking whether internal VAT classification controls were updated after the BIR guidance became available.
Deadlines and Effective Compliance Timing
RMC No. 127-2021 does not state a special transition period, grace period, or future effective date. It was issued on December 16, 2021 for the information and guidance of internal revenue officers, employees, and all others concerned. For business taxpayers, the practical implication is that the clarification should be applied in VAT classification and invoice treatment once the guidance is applicable to the product and transaction being reviewed.
Because the circular is a clarification tied to the VAT-exempt product list, taxpayers should not wait for a separate implementing issuance before correcting internal classifications. Where Liraglutide 6mg/mL Solution for Injection (SC) is sold or purchased, accounting teams should immediately confirm whether the product is tied to diabetes management or to the management of overweight and obesity under the brand name Saxenda.
Penalties and Risks for Non-Compliance
RMC No. 127-2021 does not specify a separate penalty provision. However, misclassifying a taxable product as VAT-exempt may create ordinary VAT compliance exposure under the National Internal Revenue Code and applicable BIR enforcement rules. The practical risks include incorrect VAT invoicing, under-declaration of output VAT, unsupported VAT-exempt sales reporting, mismatched accounting records, and possible exposure during BIR audit.
For buyers, the risk is also operational. If the supplier’s VAT treatment is incorrect, the buyer’s accounting records, purchase classification, expense documentation, and tax reconciliation may also be affected. Corporate purchasers, hospitals, pharmacies, and clinics should therefore ensure that the VAT treatment appearing in supplier invoices matches the actual product use and the clarification in RMC No. 127-2021.
Practical Steps for CFOs, Accountants, and Tax Managers
First, identify all product records, stock keeping units, supplier invoices, and sales entries involving Liraglutide 6mg/mL Solution for Injection (SC). The review should include product master files, invoice templates, official receipt settings, price lists, and tax mapping in accounting systems.
Second, separate transactions involving diabetes management from those involving management of overweight and obesity. For RMC No. 127-2021 compliance, this distinction is not merely medical or commercial; it determines whether VAT-exempt treatment may be supported under the clarification.
Third, check whether the product is sold under the brand name Saxenda and whether the relevant use is management of overweight and obesity. The circular expressly states that Saxenda for that purpose does not fall under the identified diseases included in both the TRAIN Law and the CREATE Act. Businesses should avoid treating that product as VAT-exempt based solely on the presence of Liraglutide 6mg/mL Solution for Injection (SC).
Fourth, update tax codes and invoicing controls. A reliable compliance setup should prevent front-line sales teams or automated systems from applying VAT exemption without the required basis. This is particularly important for drugstores, distributors, and healthcare businesses with large inventories and multiple medicine categories.
Fifth, document the basis for VAT treatment. Businesses should keep product documentation, regulatory references, internal tax memos, and supplier confirmations showing why a particular transaction was treated as VAT-exempt or not VAT-exempt. This will help support the taxpayer’s position in case of BIR audit or customer inquiry.
Why This Matters for Searches on VAT-Exempt Medicines in the Philippines
Many taxpayers search for terms such as RMC 127-2021 VAT exempt products, Liraglutide VAT exemption Philippines, Saxenda VAT Philippines, VAT-exempt medicines under TRAIN and CREATE, and diabetes medicine VAT exemption Philippines. The answer under this issuance is narrow: Liraglutide 6mg/mL Solution for Injection (SC) is VAT-exempt only if the use falls under diabetes management; Saxenda for management of overweight and obesity is not covered by the identified diseases under the TRAIN Law and the CREATE Act.
This distinction matters because VAT errors often arise when businesses classify products by active ingredient alone. RMC No. 127-2021 shows that the BIR and FDA clarification requires a closer review of the product’s indicated use and whether it falls within the statutory category relied upon for VAT exemption.
How Ablola, Saribong & Gueco Can Help
Ablola, Saribong & Gueco assists businesses, pharmacies, distributors, healthcare companies, importers, and corporate taxpayers in reviewing VAT classifications, BIR issuances, product tax mapping, invoicing controls, and audit exposure. For companies dealing with VAT-exempt medicines, border-line healthcare products, and BIR documentation requirements, early legal and tax review can prevent costly classification errors.
For assistance with RMC No. 127-2021, VAT-exempt product classification, BIR audit preparation, or tax compliance systems for pharmaceutical and healthcare businesses, contact Ablola, Saribong & Gueco through MakatiLawFirm.com.